NeoMARK (STREP) PDF | Print | E-mail

ICT enabled prediction of cancer reoccurrence (NeoMARK)

Contact the NeoMark Coordinator:

Dr Elena Martinelli

(address to be added)

email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

NeoMark participants

• Azienda Ospedaliero-Universitaria di Parma
• (Italy)
• Fraunhofer Gesellschaft Zur Foerderung der
• Angewandten Forschung E.V. (Germany)
• STMicroelectronics S.R.L. (Italy)
• Fundacion MD Anderson International España
• (Spain)
• Link Consulting – Technologias de Informaçao
• S.A. (Portugal
• Universidad Politécnica de Madrid (Spain)
• MultiMed S.R.L. (Italy)
• Panepistimio Ioanninon (Greece)
• PLANET AE (Greece)

 

NeoMark will perform research in the integration of heterogeneous clinical, laboratory, molecular and imaging data to develop a data integration environment facilitating multiscale and multilevel modeling, aimed at advancing models and methods currently in use to predict neoplastic reoccurrences, and to apply it to the study of oral cancer. Specifically the scientific target will be to apply this multi-level data integration environment to the monitoring of the disease after remission, in order to early identify local or metastatic reoccurrence of the disease.

The technical target will be the development of two functional environments: one for the definition of biomarker profiles and one for the follow-up of the evolution of the disease. They will be based on the "fusion" of information from clinical data from health records and standard laboratory markers; from histological data from tumor mass specimens; from high-throughput genomic data from tumor tissue specimens, profiling gene expression at whole-genome level by oligo-RNA microarrays; from high-throughput genomic data from circulating cells specimens (whole blood sample), profiling gene expression at whole-genome level by oligo-RNA microarrays; from imaging data of the prime tumor mass (and secondary localizations if present) through imaging techniques, including image fusion, where relevant.

The outcomes of the project will be validated in two primary Clinical Centers in Spain and in Italy. In this phase the early exploitation of NeoMark will also be assessed through the use of a RT-PCR platform to develop highly individual diagnostic tests to be used both at the time of first diagnosis, as well as for reoccurrence identification.

For more information on NeoMARK click here